DRUG

Bright Minds Biosciences Inc.

Fundamental data last updated:September 27, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

CA

Next Earnings Date

Pending Announcement

Business Summary

Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.

 


Analyze DRUG on TradingView

VALUATION

P/E

-31.21

Market Cap ($M USD)

$694.58M

Forward P/E

-10.25

PEG

0.05

PRICE TO SALES

0.00

PRICE TO BOOK

3.83

EV / EBITDA

-20.58

5-Year Average P/E

Free Cash Flow Yield

-2.10%

DCF Value

$8.59

Graham Number

N/A

Price to FCF

-47.51

EV to FCF

-32.13

Earnings Yield

-2.34%

FCF Yield

-2.10%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$2.87

Next Year EPS Growth Estimate

-$8.73

Next Year Revenue Growth Estimate

$0.00

Return on Equity (ROE)

-20.73%

FREE CASH FLOW

Operating Margin

0.00%

Debt-to-Equity

0.00

Piotroski F-Score

1

Altman Z-Score

145.43

Return on Invested Capital (ROIC)

-10.21%

Current Ratio

81.48

Quick Ratio

81.48

Net Debt to EBITDA

9.85

Interest Coverage

-2438.56

Gross Profit margin

0.00%

FCF PER SHARE

$-2.09

REVENUE PER SHARE

$0.00

Analyze DRUG on TradingView

Gainseekers Quantitative Analysis

Summary

The market seems to be pricing Bright Minds Biosciences Inc. with a level of optimism that defies its fundamentals. Despite a staggering Altman Z-score suggesting financial safety, the stock traded significantly above its DCF value, indicating potential overvaluation. The negative Forward P/E and Earnings Yield highlight a company struggling with profitability, while the Piotroski F-Score of 1 raises red flags about operational efficiency. The market cap suggests a substantial size, yet the lack of earnings and negative ROIC paint a picture of a company not yet delivering on its promises.

AI Exposure / Tech Reliance

In the rapidly evolving biotechnology sector, Bright Minds Biosciences is well-positioned to leverage AI for drug discovery and personalized medicine. However, the industry's inherent volatility and long development cycles pose challenges. The company's adaptability to tech shifts will be crucial for its future success.

The Bull Case

For a GARP investor, the allure lies in the company's potential for growth despite its current challenges. The exceptionally low Debt/Equity ratio indicates financial prudence, while the high Altman Z-score suggests resilience. Although the ROIC is negative, the company's strong liquidity, as evidenced by its Current and Quick Ratios, provides a cushion for future investments. The consensus rating of "Buy" implies institutional confidence in its long-term prospects.

The Bear Case

The bear case is hard to ignore with Bright Minds Biosciences. The Price/Book ratio is alarmingly high, suggesting the stock is priced for perfection without the earnings to back it up. The negative EV to EBITDA and Price to FCF ratios highlight severe cash flow issues, while the stock's proximity to its 52-week high suggests technical overextension. The lack of sales growth and zero operating margin further underscore the company's struggle to generate revenue.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$164.33

Institutional Ownership %

1-Year Beta

-0.19

Insider Buying % (6 Mo)

Distance to 52-Week High

38.28%

Distance to 52-Week Low

74.10%

EARNINGS SURPRISE %

31.62%

50-DAY SMA

$82.04

200-DAY SMA

$70.88

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.